ME01245B - Antibakterijski hinolinski derivati - Google Patents
Antibakterijski hinolinski derivatiInfo
- Publication number
- ME01245B ME01245B MEP-2011-141A MEP14111A ME01245B ME 01245 B ME01245 B ME 01245B ME P14111 A MEP14111 A ME P14111A ME 01245 B ME01245 B ME 01245B
- Authority
- ME
- Montenegro
- Prior art keywords
- alkyl
- aryl
- compound according
- het
- mono
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- -1 cyano, formyl Chemical group 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 3
- 125000005984 hexahydro-1H-1,4-diazepinyl group Chemical group 0.000 claims 3
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 3
- 125000004306 triazinyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- VZLKQEPNZIWSFF-UHFFFAOYSA-N 1-pyrrolidin-1-ylpiperidine Chemical compound C1CCCN1N1CCCCC1 VZLKQEPNZIWSFF-UHFFFAOYSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005094 alkyl carbonyl amino alkyl group Chemical group 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (21)
1. Jedinjenje, naznačeno time, da je predstavljeno formulom (Ia) ili (lb) uključujući i sve njegove stereohemijske izomerne forme, gde p je neki celi broj koji je jednak 1, 2, 3 ili 4;q je neki celi broj koji je jednak nuli, 1, 2, 3 ili 4;R1 je vodonik, cijano, formil, karboksil, halo, alkil, C2-6alkenil, C2-6alkinil, haloalkil, hidroksi, alkiloksi, alkiltio, alkiltioalkil -C=N-OR11, amino, mono ili di(alkil)amino, aminoalkil, mono ili di(alkil)aminoalkil, alkilkarbonilaminoalkil, aminokarbonil, mono ili di(alkil)aminokarbonil, arilalkil, arilkarbonil, R5aR4aNalkil, di(aril)alkil, aril, R5aR4aN-, R5aR4aN-C(=0)- ili Het;R2 je vodonik, alkiloksi, aril, ariloksi, hidroksi, merkapto, alkiloksialkiloksi, alkiltio,mono ili di(alkil)amino, pirolidino ili neki radikal sa formulomgde Y je CH2, O, S, NH ili N-alkil;R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, aril-aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili R4 i R5 svaki nezavisno je vodonik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono-ili dialkilaminoalkil; biciklo[2.2.1]heptil; Het; aril; ili -C(=NH)-NH2; iliR4 i R5 zajedno sa atomom azota, na kojeg su vezani, formiraju neki radikal koji je izabran iz grupe koja obuhvata pirolidino, piperidin, piperazino, morfolino, 4-tiomorfolino, 1,1-dioksid-tiomorfolinil, azetidinil, 2,3- dihidroizoindol-l-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro- 1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizohinolin-2-il, 2,5-diazabiciklo[2.2,1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, a svaki radikal je ponekad supstituisan sa 1, 2, 3 ili 4 supstituenata, a svaki supstituenat je nezavisno izabran iz alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, aminoalkila, mono- ili dialkilaminoalkila, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila koji je ponekad supstituisan sa alkilom ili pirolidinilom koji je ponekad supstituisan sa arilalkilom;R4a i R5a zajedno sa atomom azota, na kojeg su spojeni, formiraju neki radikal koji je izabran iz grupe koja obuhvata pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-l-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4- diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizohinolin-2-il, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, a svaki radikal je ponekad supstituisan sa 1, 2, 3 ili 4 supstituenata, a svaki supstituenat je nezavisno izabran iz alkila, haloalkila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila ili pirimidinila;R7 je vodonik, halo, alkil, aril ili Het;R8 je vodonik ili alkil;R9 je okso; iliR8 i R9 zajedno formiraju radikal -CH=CH-N=;R11 je vodonik ili alkil;aril je neki homocikal koji je izabran iz fenila, naftila, acenaftila ili tetrahidronaftila, asvaki od njih je ponekad supstituisan sa 1, 2 ili 3 supstituenata, a svaki supstituenat je nezavisno izabran iz hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, C2-6alkenila koji je ponekad supstituisan sa fenilom, haloalkilom, alkiloksi, haloalkiloksi, karboksilom,alkiloksikarbonilom, aminokarbonilom, morfolinilom ili mono- ili dialkilaminokarbonilom;Het je neki monociklički heterocikal koji je izabran iz N-fenoksipiperidinila, piperidinila, pirolila, pirazolila, imidazolila, furanila, tienila, oksazolila, izoksazolila, tiazolila, izotiazolila, piridinila, pirimidinila, pirazinila ili piridazinila; ili neki biciklički heterocikal koji je izabran izhinolinila, kinoksalinila, indolila, benzimidazolila, benzoksazolila, benzizoksazolila, benzotiazolila, benzizotiazolila, benzofuranila, benzotienila, 2,3- dihidrobenzo[l,4]dioksinila ili benzo[l,3]dioksolila; a svaki monociklički ili biciklički heterocikal je ponekad supstituisan sa 1, 2ili 3 supstituenata, a svaki supstituenat je nezavisno izabran iz halo, hidroksi, alkila ili alkiloksi; neki njegov N-oksid, njegova farmaceutski prihvatljiva so ili njegov solvat.
2.Jedinjenje u skladu sa zahtevom 1, naznačeno time, da R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili R4 i R5 svaki nezavisno je vodonik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; Het; aril; ili -C(=NH)-NH2; ili R4 i R5 zajedno sa atomom azota, na kojeg su spojeni, formiraju neki radikal koji je izabran iz grupe koja obuhvata pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-l-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-lHazepinil, heksahidro-lH-l,4- diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizohinolin-2-il, 2,5-diazabiciklo[2.2.1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, a svaki radikal je ponekad supstituisan sa 1,2, 3 ili 4 supstituenata, a svaki supstituenat je nezavisno izabran iz alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila ili pirolidinila koji je ponekad supstituisan sa arilalkilom; aril je neki homocikal koji je izabran iz fenila, naftila, acenaftila ili tetrahidronaftila, a svaki od njih je ponekad supstituisan sa 1, 2 ili 3 supstituenata, a svaki supstituenat je nezavisno izabran iz hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, haloalkila, alkiloksi, haloalkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila ili mono- ili dialkilaminokarbonila.
3.Jedinjenje u skladu sa zahtevom 1 ili 2, naznačeno time, da alkil predstavlja C1-6alkil.
4.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da R1 je halo, Het ili aril.
5.Jedinjenje u skladu sa zahtevom 4, naznačeno time, da R1 je halo.
6. Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da p je jednak 1.
7.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da R2 je C1-6alkiloksi.
8.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da R3 je aril.
9.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da q je jednak 2, 3 ili 4.
10.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da R4 i R5 predstavljaju C1-6alkil.
11.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da R7 je vodonik.
12.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da pomenuto jedinjenje je neko jedinjenje sa formulom (Ia).
13.Jedinjenje u skladu sa zahtevom 12, naznačeno time, da R1 je halo; R2 je C1-6alkiloksi; R8 je aril; R4 i R5 su C1-6alkil; R7 je vodonik; q je 2, 3 ili 4; a p je 1.
14.Jedinjenje u skladu sa bilo kojim od prethodnih zahteva, naznačeno time, da se pomenuto jedinjenje koristi kao lek.
15.Jedinjenje u skladu sa bilo kojim od zahteva od 1 do 13, naznačeno time, da se pomenuto jedinjenje koristi kao lek za tretman bakterijske infekcije uključujući i neku mikobakterijsku infekciju.
16.Farmaceutska kompozicija, naznačena time, da obuhvata neki farmaceutski prihvatljivi nosač i, kao aktivan sastojak, terapeutski efektivnu količinu nekog jedinjenja kao šta je definisano u bilo kojem od zahteva od 1 do 13.
17.Jedinjenje u skladu sa zahtevom 15, naznačeno time, da pomenuta bakterijska infekcija je neka infekcija sa nekom gram-pozitivnom bakterijom.
18.Jedinjenje u skladu sa zahtevom 15, naznačeno time, da pomenuta gram-pozitivna bakterija je Streptococcus pneumoniae ili Staphilococcus aureus.
19.Kombinacija, naznačena time, da obuhvata (a) neko jedinjenje u skladu sa bilo kojim od zahteva od 1 do 13 i (b) jedan ili više drugih antibakterijskih agenasa.
20.Produkt, naznačen time, da sadrži (a) neko jedinjenje u skladu sa bilo kojim od zahteva od 1 do 13 i (b) jedan ili više drugih antibakterijskih agenasa, u formi kombinovane preparacije za simultano, odvojeno ili sekvencijalno korišćenje u tretmanu neke bakterijske infekcije.
21.Jedinjenje u skladu sa zahtevom 18, naznačeno time, da pomenuta gram-pozitivna bakterija je Staphilococcus aureus koji je otporan na meticilin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125529 | 2006-12-06 | ||
| EP07847814A EP2099759B1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
| PCT/EP2007/063316 WO2008068270A1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01245B true ME01245B (me) | 2013-06-20 |
Family
ID=38124123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-141A ME01245B (me) | 2006-12-06 | 2007-12-04 | Antibakterijski hinolinski derivati |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20110166179A1 (me) |
| EP (1) | EP2099759B1 (me) |
| JP (1) | JP5356246B2 (me) |
| KR (1) | KR101526175B1 (me) |
| CN (1) | CN101553471B (me) |
| AR (1) | AR064152A1 (me) |
| AT (1) | ATE509915T1 (me) |
| AU (1) | AU2007328890B2 (me) |
| BR (1) | BRPI0720133A2 (me) |
| CA (1) | CA2669829C (me) |
| CL (1) | CL2007003517A1 (me) |
| CY (1) | CY1112230T1 (me) |
| DK (1) | DK2099759T3 (me) |
| ES (1) | ES2366062T3 (me) |
| HR (1) | HRP20110540T1 (me) |
| IL (1) | IL199084A0 (me) |
| JO (1) | JO2725B1 (me) |
| ME (1) | ME01245B (me) |
| MX (1) | MX2009005981A (me) |
| NO (1) | NO342774B1 (me) |
| NZ (1) | NZ577069A (me) |
| PL (1) | PL2099759T3 (me) |
| PT (1) | PT2099759E (me) |
| RS (1) | RS51848B (me) |
| RU (1) | RU2439058C2 (me) |
| SI (1) | SI2099759T1 (me) |
| TW (1) | TWI487525B (me) |
| WO (1) | WO2008068270A1 (me) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102844304B (zh) * | 2010-01-04 | 2014-12-31 | 日本曹达株式会社 | 含氮杂环化合物以及农园艺用杀菌剂 |
| AR086411A1 (es) | 2011-05-20 | 2013-12-11 | Nippon Soda Co | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| US9133167B2 (en) | 2012-04-27 | 2015-09-15 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| KR102110366B1 (ko) * | 2012-04-27 | 2020-05-14 | 얀센 파마슈티카 엔.브이. | 항균성 퀴놀린 유도체 |
| CN106806367A (zh) * | 2015-09-29 | 2017-06-09 | 王洪燕 | 一种治疗烧伤后感染的药物组合物 |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2220960C2 (ru) * | 1997-12-22 | 2004-01-10 | Фармация Энд Апджон Компани | 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе |
| PT1527050E (pt) * | 2002-07-25 | 2010-06-22 | Janssen Pharmaceutica Nv | Derivados de quinolina e sua utilização como inibidores de micobactérias |
| ATE444068T1 (de) * | 2004-01-23 | 2009-10-15 | Janssen Pharmaceutica Nv | Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren |
| JO2524B1 (en) * | 2004-05-28 | 2010-03-17 | جانسن فارمسيتكا ان في | Use of substituted quinoline derivatives to treat drug-resistant microbial diseases |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
-
2007
- 2007-11-29 JO JO2007506A patent/JO2725B1/en active
- 2007-12-04 US US12/516,396 patent/US20110166179A1/en not_active Abandoned
- 2007-12-04 MX MX2009005981A patent/MX2009005981A/es active IP Right Grant
- 2007-12-04 BR BRPI0720133-8A patent/BRPI0720133A2/pt not_active Application Discontinuation
- 2007-12-04 HR HR20110540T patent/HRP20110540T1/hr unknown
- 2007-12-04 AT AT07847814T patent/ATE509915T1/de active
- 2007-12-04 PL PL07847814T patent/PL2099759T3/pl unknown
- 2007-12-04 NZ NZ577069A patent/NZ577069A/en not_active IP Right Cessation
- 2007-12-04 ME MEP-2011-141A patent/ME01245B/me unknown
- 2007-12-04 JP JP2009539741A patent/JP5356246B2/ja not_active Expired - Fee Related
- 2007-12-04 RU RU2009125520/04A patent/RU2439058C2/ru active
- 2007-12-04 AU AU2007328890A patent/AU2007328890B2/en not_active Ceased
- 2007-12-04 SI SI200730665T patent/SI2099759T1/sl unknown
- 2007-12-04 RS RS20110354A patent/RS51848B/sr unknown
- 2007-12-04 CN CN2007800454055A patent/CN101553471B/zh not_active Expired - Fee Related
- 2007-12-04 CA CA2669829A patent/CA2669829C/en active Active
- 2007-12-04 WO PCT/EP2007/063316 patent/WO2008068270A1/en not_active Ceased
- 2007-12-04 KR KR1020097013237A patent/KR101526175B1/ko not_active Expired - Fee Related
- 2007-12-04 EP EP07847814A patent/EP2099759B1/en active Active
- 2007-12-04 ES ES07847814T patent/ES2366062T3/es active Active
- 2007-12-04 DK DK07847814.6T patent/DK2099759T3/da active
- 2007-12-04 PT PT07847814T patent/PT2099759E/pt unknown
- 2007-12-05 CL CL200703517A patent/CL2007003517A1/es unknown
- 2007-12-05 AR ARP070105445A patent/AR064152A1/es unknown
- 2007-12-05 TW TW096146211A patent/TWI487525B/zh not_active IP Right Cessation
-
2009
- 2009-06-02 IL IL199084A patent/IL199084A0/en active IP Right Grant
- 2009-07-06 NO NO20092547A patent/NO342774B1/no unknown
-
2011
- 2011-08-10 CY CY20111100772T patent/CY1112230T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| HRP20100428T1 (hr) | Antibakterijski derivati kvinolina | |
| JP2010511667A5 (me) | ||
| HRP20131116T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20110540T1 (hr) | Antibakterijski derivati kinolina | |
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| HRP20080307T3 (hr) | Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekove | |
| ME01207B (me) | Derivati hinolina za tretiranje latentne tuberkuloze | |
| JP2010511671A5 (me) | ||
| JP2009503024A5 (me) | ||
| CA3081423A1 (en) | Antibacterial compounds | |
| HRP20160252T1 (hr) | C-4" položaj supstituiranog derivata makrolida | |
| HRP20140206T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| ME01073B (me) | Antibakterijski derivati kvinolina | |
| JP2010511670A5 (me) | ||
| AR064148A1 (es) | Derivados de quinolina antibacterial | |
| AR064147A1 (es) | Derivados de quinolina antibacterianos | |
| AR054587A1 (es) | Derivados de quinolina antibacterianos | |
| HRP20170044T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20120910T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2010511672A5 (me) | ||
| ME01484B (me) | Kinolinski derivati kao antibakterijski agensi | |
| ME02690B (me) | Derivati kvinolina kao antibakterijski agensi | |
| JP2009503021A5 (me) | ||
| JP2008543964A5 (me) |